OBI Pharma announces participation at the 36th J.P. Morgan Annual Healthcare Conference in San Francisco from January 8-10, 2018.

Taipei, Taiwan, December 22, 2017 6:00pm – OBI Pharma, Inc. (TPEx:4174), a Taiwan biopharma company specializing in the development of novel first-in-class cancer therapeutics that uniquely target Globo Series (including Globo H) and AKR1C3, announced that it will participate at the 36th J.P. Morgan Annual Healthcare Conference. The conference is being held on January 8-11, […]

HOMEWhat’s NewNewsOBI Pharma announces participation at the 36th J.P. Morgan Annual Healthcare Conference in San Francisco from January 8-10, 2018.

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2017.Oct.30

OBI Pharma announces OBI-3424 results from the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2018.Jan.17

OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy (OBI-888)